港股異動 | 創科實業續跌5%創逾2個月新低 市值跌破1500億港元
格隆匯9月27日丨創科實業(0669.HK)延續跌勢,再度跌5%,9月中旬以來累計跌幅近20%,現報81.1港元創逾2個月新低,總市值跌破1500億港元。在全球通脹以及國際衝突下,市場對其業績普遍悲觀。有分析稱,創科實業基本面依舊強硬,但也不是説完全沒有風險,目前該公司面臨的最大風險是國際衝突以及匯率波動風險。該公司業務是覆蓋全球的,每個地區市場使用不同的貨幣交易,結算成美元可能會存在匯率損失。據瞭解,今年上半年其海外匯兑差額虧損0.99億美元,同時國際衝突也會影響地區性的穩定運營。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.